

Case Number:

100221927023

Patient Name:

Sohanlal Kataria

Age/Sex:

67 Yrs/Male

Patient Location:

Mumbai

Hospital Name:

Aasha Cancer Hospital

Physician Name:

Dr. Vashishth Maniar

Date &amp; Time of Accessioning:

23/11/2021 10:33 Hrs

Date &amp; Time of Reporting:

03/12/2021 18:15 Hrs

## TEST NAME

NTRK 1/2/3 Gene Fusion Panel

## SPECIMEN INFORMATION

Received one paraffin block labeled with 21MLH-35987.

## CLINICAL HISTORY


Metastatic poorly differentiated adenocarcinoma

## METHODOLOGY


Fluorescence In Situ Hybridization (FISH)

## RESULTS


Chromosome abnormality screened	Results	% abnormal
NTRK1 gene rearrangement (1q21.3) (ZytoLight SPEC NTRK1 Dual Color Break Apart Probe)	Negative	0
NTRK2 gene rearrangement (9q21.3) (ZytoLight SPEC NTRK2 Dual Color Break Apart Probe)	Negative	0
NTRK3 gene rearrangement (15q25.3) (ZytoLight SPEC NTRK3 Dual Color Break Apart Probe)	Negative	0



NTRK1 (1q21.3)



NTRK2 (9q21.3)



NTRK3 (15q25.3)

Sample is considered negative	<10% cells are positive.
Sample is considered positive	>15% cells are positive
Sample is considered equivocal	<10 to 15% cells are positive.

Dr. Mohit Kumar, Ph. D.

Dr. Shivani Sharma, DCP, DNB  
Reg. No. 1906

Case Number:	100221927023
Patient Name:	Sohanlal Kataria
Age/Sex:	67 Yrs/Male
Patient Location:	Mumbai
Hospital Name:	Aasha Cancer Hospital
Physician Name:	Dr. Vashishth Maniar
Date & Time of Accessioning:	23/11/2021 10:33 Hrs
Date & Time of Reporting:	03/12/2021 18:15 Hrs

## INTERPRETATION

The result is negative for NTRK gene panel rearrangement encompassing NTRK1, NTRK2 and NTRK3 genes

## COMMENTS

1. In NSCLC, NTRK fusions are estimated to occur at a frequency of approximately 0.1% to 1%.
2. Furthermore, NTRK gene fusions in NSCLC seemed associated with levels of TMB and frequencies of PD-L1 expression higher than other molecularly defined subgroups (EGFR, ALK and ROS1 altered cases) and co-exist with STK11 mutations, which have been associated with decreased efficacy to immune checkpoint inhibitors, at frequencies similar to NSCLC in general but lower than the frequency in lung adenocarcinoma only. The TRK inhibitors namely,
3. Larotrectinib (LOXO-101) and Entrectinib (RXDX- 101) are oral tyrosine kinase inhibitor that have high selectivity and potency for TRKA, TRKB, and TRKC (Drilon et al., 2017, Coco et al., 2018).

## REFERENCES

- Drilon A, Siena S, Ou SI et al. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017 Apr;7(4):400-409.
- Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018 Dec;15(12):731-747.



Dr. Mohit Kumar, Ph. D.



Dr. Shivani Sharma, DCP, DNB  
Reg. No. 1906

If you have any questions about this report or would like to have a conversation about the genetic implications of these test results, please feel free to reach out to us at

**1800 103 2673 (Toll Free) or [geneCORE@corediagnostics.in](mailto:geneCORE@corediagnostics.in)**

to schedule a session with our resident genetic counselor

### CONDITIONS OF REPORTING

1. The tests are carried out in the lab with the presumption that the specimen belongs to the patient named or identified in the bill/test request form.
2. The test results relate specifically to the sample received in the lab and are presumed to have been generated and transported per specific instructions given by the physicians/laboratory.
3. The reported results are for information and are subject to confirmation and interpretation by the referring doctor.
4. Some tests are referred to other laboratories to provide a wider test menu to the customer.
5. CORE Diagnostics Pvt. Ltd. shall in no event be liable for accidental damage, loss, or destruction of specimen, which is not attributable to any direct and mala fide act or omission of CORE Diagnostics Pvt. Ltd. or its employees. Liability of CORE Diagnostics Pvt. Ltd. for deficiency of services, or other errors and omissions shall be limited to fee paid by the patient for the relevant laboratory services.

This is a transcribed report and the test was performed at the laboratory OSL 11.

This report is the property of CORE Diagnostics. The information contained in this report is strictly confidential and is only for the use of those authorized. If you have received this report by mistake, please contact CORE Diagnostics.